daprodustat (Rx)

Brand and Other Names:Jesduvroq

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 1mg
  • 2mg
  • 4mg
  • 6mg
  • 8mg

Anemia of Chronic Kidney Disease

Indicated for treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for ≥4 months

Individualize dosing and use lowest dose sufficient to reduce need for red blood cell (RBC) transfusions

Do not target a hemoglobin >11 g/dL

Dosing in patients not treated with an erythropoietin-stimulating agent (ESA)

  • Starting dose is based on pretreatment hemoglobin (Hgb) level
  • Hgb <9 g/dL: Start at 4 mg PO qDay
  • 9-10 g/dL: Start at 2 mg PO qDay
  • >10 g/dL: Start at 1 mg PO qDay

Switching from an ESA

  • Starting dose of daprodustat is based on dosing regimen of ESA at time of substitution
  • Epoetin alfa IV
    • Note: For patients on SC epoetin alfa, convert epoetin alfa SC dose to IV dose equivalent by multiplying SC dose received per week by 1.42 to obtain weekly IV dose
    • ≤2,000 units/week: Start daprodustat at 4 mg PO qDay
    • >2,000 to <10,000 units/week: Start daprodustat at 6 mg PO qDay
    • ≥10,000 to <20,000 units/week: Start daprodustat at 8 mg PO qDay
    • ≥20,000 units/week: Start daprodustat at 12 mg PO qDay
  • Darbepoetin alfa IV/SC
    • 20-30 mcg/4 weeks: Start daprodustat at 4 mg PO qDay
    • >30 to 150 mcg/4 weeks: Start daprodustat at 6 mg PO qDay
    • >150 to 300 mcg/4 weeks: Start daprodustat at 8 mg PO qDay
    • >300 mcg/4 weeks: Start daprodustat at 12 mg PO qDay
  • Methoxy polyethylene glycol (PEG)-epoetin beta SC/IV
    • 30-40 mcg/month: Start daprodustat at 4 mg PO qDay
    • >40 to 180 mcg/month: Start daprodustat at 6 mg PO qDay
    • >180 to 360 mcg/month: Start daprodustat at 8 mg PO qDay
    • >360 mcg/month: Start daprodustat at 12 mg PO qDay

Dosage Modifications

Recommended dose levels

  • 1 mg/day
  • 2 mg/day
  • 4 mg/day
  • 6 mg/day
  • 8 mg/day
  • 12 mg/day
  • 16 mg/day
  • 24 mg/day (maximum recommended dose)

Dosage adjustments

  • When adjusting doses, consider Hgb rate of rise, rate of decline, and variability
  • Do not increase dose more frequently than once q4Weeks
  • If dose needs to be adjusted, increase or decrease by 1 dose level at a time
  • Decrease dose
    • Hgb increases rapidly (eg, >1 g/dL over 2 weeks or >2 g/dL over 4 weeks), OR
    • Hgb >11 g/dL
  • Interrupt treatment
    • Hgb >12 g/dL
    • Restart at 1 dose level lower once Hgb is within target range
    • Do not continue therapy beyond 24 weeks if no clinically meaningful increase in Hgb is achieved
    • Seek alternative explanations for an inadequate response and treat before restarting

Coadministration with moderate CYP2C8 inhibitors

  • Coadministration with clopidogrel or moderate CYP2C8 inhibitor: Reduce starting dose by half except in patients whose starting dose is 1 mg
  • Monitor Hgb and adjust dose when initiating or stopping therapy with clopidogrel or moderate CYP2C8 inhibitor during treatment

Renal impairment

  • Steady-state exposure of daprodustat is similar in patients with normal renal function and those with varying degrees of renal impairment
  • Hemodialysis or peritoneal dialysis
    • Daprodustat exposure not significantly impacted
    • Systemic exposure of daprodustat metabolites was higher in patients with Stage 3-5 CKD than in those with normal renal function
    • Exposures of metabolites were higher on non-dialysis days than on dialysis days

Hepatic impairment

  • Mild (Child-Pugh Class A): No dosage adjustment necessary
  • Moderate (Child-Pugh Class B): Reduce starting dose by half except in patients whose starting dose is 1 mg
  • Severe (Child-Pugh C): Not studied; not recommended

Dosing Considerations

Monitoring response to therapy

  • Following initiation and after each dose adjustment, monitor Hgb q2Weeks for first month and then q4Weeks thereafter

Anemia or iron status

  • Correct and exclude other causes of anemia (eg, vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) before initiating
  • Evaluate iron status before and during treatment
  • Serum ferritin <100 mcg/mL or serum transferrin saturation <20%: Administer supplemental iron therapy
  • Majority of patients with CKD will require supplemental iron during course of therapy

Liver testing

  • Assess serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin before initiating
  • Repeat liver tests if signs or symptoms consistent with liver disease develop during treatment

Limitations of use

  • Not shown to improve quality of life, fatigue, or patient well-being
  • Not indicated
    • As a substitute for RBC transfusion in patients requiring immediate correction of anemia
    • For patients not on dialysis

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and daprodustat

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (0)

                    Previous
                    Next:

                    Adverse Effects

                    >10%

                    Hypertension (24%)

                    Abdominal pain (11%)

                    1-10%

                    Dizziness (7%)

                    Hypersensitivity (7%)

                    Vascular access thrombosis (5%)

                    Myocardial infarction (3.4%)

                    Stroke (1.2%)

                    <1%

                    Deep vein thrombosis (0.7%)

                    Pulmonary embolism (0.3%)

                    Previous
                    Next:

                    Warnings

                    Black Box Warnings

                    Increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access

                    • Increased risk of thrombotic vascular events, including major adverse cardiovascular events (MACE)
                    • Hemoglobin rise >1 g/dL over 2 weeks may contribute to these risks
                    • Target hemoglobin level >11 g/dL is expected to further increase risk of death and arterial venous thrombotic events, as occurs with erythropoietin-stimulating agents (ESAs), which also increase erythropoietin levels
                    • No trial has identified a hemoglobin target level, daprodustat dose, or dosing strategy that avoids these risks
                    • Use lowest dose to reduce need for red blood cell transfusion
                    • Avoid use in patients with a history of myocardial infarction, cerebrovascular event, or acute coronary syndrome within 3 months before starting

                    Contraindications

                    Strong CYP2C8 inhibitors (eg, gemfibrozil)

                    Uncontrolled hypertension

                    Cautions

                    Increased risk of cardiovascular mortality, stroke, thromboembolism, serious acute kidney injury, hospitalization for heart failure, and serious gastrointestinal erosions observed

                    Advise patients to seek immediate medical attention if signs or symptoms of MI, stroke, VTE, or thrombosis of vascular access develop; evaluate and manage promptly if these occur (see Black Box Warning)

                    Hospitalization for heart failure reported; consider patient’s history of heart failure before prescribing; advise patients on signs and symptoms of heart failure and to immediately their healthcare provider if these symptoms worsen

                    Contraindicated in uncontrolled hypertension; periodically monitor blood pressure and adjust or initiate antihypertensive therapy as needed

                    Safety not established for treatment of anemia due to CKD in adults not on dialysis; use not recommended in this setting

                    Not studied and not recommended in patients with active malignancies; malignancies reported

                    Gastrointestinal erosion

                    • Gastric or esophageal erosions occurred
                    • Consider this risk particularly in patients with risk factors for gastrointestinal (GI) erosions, such as history of GI erosion, peptic ulcer disease, concomitant use of medications that increase the risk of GI erosion, current tobacco smoking, and alcohol use
                    • Advise patients of symptoms and signs of gastric and esophageal erosions and of GI bleeding and to seek prompt medical care if these occur

                    Drug interaction overview

                    • CYP2C8 substrate
                    • Strong CYP2C8 inhibitors (eg, gemfibrozil)
                      • Contraindicated
                      • Strong CYP2C8 inhibitors are contraindicated due to marked increase in daprodustat exposure
                    • Moderate CYP2C8 inhibitors (eg, clopidogrel)
                      • Reduce daprodustat dose by half when initiating moderate CYP2C8 inhibitors, except with a starting dose of 1 mg/day
                      • Monitor Hgb and adjust daprodustat dose when initiating or stopping moderate CYP2C8 inhibitor
                      • Moderate CYP2C8 inhibitors increase daprodustat exposure
                    • CYP2C8 inducers (eg, rifampin)
                      • Monitor Hgb and adjust dose when initiating or stopping therapy with CYP2C8 inducers during treatment
                      • CYP2C8 inducers may decrease exposure and efficacy of daprodustat
                    Previous
                    Next:

                    Pregnancy & Lactation

                    Pregnancy

                    Available data are insufficient in pregnant females to establish a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes

                    Animal data

                    • Oral administration to pregnant rats and rabbits during organogenesis was associated with adverse fetal outcomes (eg, embryonic and fetal loss, reduced fetal weight) at doses that caused maternal toxicity and polycythemia
                    • Advise pregnant females regarding potential risk to fetus

                    Clinical consideration

                    • CKD during pregnancy increases risk for maternal hypertension, preeclampsia, miscarriage, stillbirth, preterm delivery, low birth weight infants, and polyhydramnios

                    Lactation

                    There are no data on drug presence in human milk, effects on breastfed infants, or effects on milk production

                    Daprodustat is present in the milk of lactating rats

                    When a drug is present in animal milk, it is likely that drug will be present in human milk

                    Advise patients not to breastfeed during treatment and for 1 week after final dose

                    Pregnancy Categories

                    A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                    B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                    C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                    D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                    X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                    NA: Information not available.

                    Previous
                    Next:

                    Pharmacology

                    Mechanism of Action

                    Reversible inhibitor of hypoxia inducible factor (HIF)-PH1, PH2, and PH3

                    Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilizes hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anemia

                    Daprodustat increases endogenous erythropoietin in a dose-dependent manner

                    Also increases serum transferrin and total iron binding capacity (TIBC) and decreased serum ferritin, transferrin saturation, and hepcidin when administered for 52 weeks in adults on dialysis with anemia due to CKD

                    Absorption

                    Peak plasma time: 1-4 hr

                    Bioavailability: 65%

                    Steady-state achieved within 24 hr of dosing

                    Effects of food

                    • High-fat/high-calorie: No significant changes in daprodustat exposure compared with fasted state

                    Distribution

                    Vd (steady-state): 14.3 L (healthy subjects)

                    Protein bound: > 99%

                    Metabolism

                    Primarily metabolized by CYP2C8 (95%); minor contribution by CYP3A4 (5%)

                    Elimination

                    Half-life: 1-4 hr

                    Clearance: 18.9 L/hr (plasma)

                    Excretion: Feces (74%); urine (21%); ~99.5% of dose excreted as oxidative metabolites and remainder as daprodustat

                    Previous
                    Next:

                    Administration

                    Oral Administration

                    May take with or without food

                    May take without regard to concomitant administration of iron or phosphate binders

                    Swallow tablet whole; do NOT cut, crush, or chew

                    Administer without regard to timing or type of dialysis

                    Missed dose

                    • Take as soon as possible, unless it is the same day as next scheduled dose
                    • In this case, skip missed dose, and take next dose at scheduled time; do NOT double dose

                    Storage

                    Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)

                    Previous
                    Next:

                    Images

                    No images available for this drug.
                    Previous
                    Next:

                    Patient Handout

                    A Patient Handout is not currently available for this monograph.
                    Previous
                    Next:

                    Formulary

                    FormularyPatient Discounts

                    Adding plans allows you to compare formulary status to other drugs in the same class.

                    To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                    Adding plans allows you to:

                    • View the formulary and any restrictions for each plan.
                    • Manage and view all your plans together – even plans in different states.
                    • Compare formulary status to other drugs in the same class.
                    • Access your plan list on any device – mobile or desktop.

                    The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                    Tier Description
                    1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                    2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                    3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                    4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    NC NOT COVERED – Drugs that are not covered by the plan.
                    Code Definition
                    PA Prior Authorization
                    Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                    QL Quantity Limits
                    Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                    ST Step Therapy
                    Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                    OR Other Restrictions
                    Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                    Additional Offers
                    Email to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Email Forms to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Previous
                    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.